LENZ THERAPEUTICS, INC.

News LENZ Therapeutics, Inc.

Equities

LENZ

US52635N1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
16.18 ^USD	-1.52%		+2.34%	0.00%

Apr. 15	Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	MT
Apr. 15	William Blair Starts LENZ Therapeutics With Outperform Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	May. 08	GL
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024	May. 01	GL
Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	Apr. 15	MT
William Blair Starts LENZ Therapeutics With Outperform Rating	Apr. 15	MT
LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials	Apr. 03	MT
LENZ Therapeutics, Inc. Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	Apr. 03	CI
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study	Apr. 03	RE
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	Apr. 03	BU
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials	Apr. 02	BU
Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target	Mar. 27	MT
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to NASDAQ Composite Index	Mar. 24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
LENZ Stock
News LENZ Therapeutics, Inc.

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW